Zobrazeno 1 - 10
of 111
pro vyhledávání: '"MESH: Immunotherapy"'
Autor:
Rousset, Perrine, Dalle, Stéphane, Mortier, Laurent, Dereure, Olivier, Dalac, Sophie, Dutriaux, Caroline, Leccia, Marie-Thérèse, Legoupil, Delphine, Brunet-Possenti, Florence, de Quatrebarbes, Julie, Grob, Jean-Jacques, Saiag, Philippe, Maubec, Eve, Stoebner, Pierre-Emmanuel, Granel-Brocard, Florence, Arnault, Jean-Philippe, Allayous, Clara, Oriano, Bastien, Lebbé, Celeste, Montaudié, Henri
Publikováno v:
Journal of The American Academy of Dermatology
Journal of The American Academy of Dermatology, 2023, 88 (4), pp.808-815. ⟨10.1016/j.jaad.2022.11.040⟩
Journal of The American Academy of Dermatology, 2023, 88 (4), pp.808-815. ⟨10.1016/j.jaad.2022.11.040⟩
International audience; Background: Clinical outcomes of advanced melanoma of unknown primary (MUP) in the era of novel therapies have been scarcely studied.Objective: To investigate the efficacy and safety of systemic treatments in patients with adv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::710dbf1cc61bbf8b206c0b976465dba7
https://hal.science/hal-04052676
https://hal.science/hal-04052676
Autor:
Sonia Guedan, Maik Luu, Delphine Ammar, Paula Barbao, Chiara Bonini, Philippe Bousso, Christian J Buchholz, Monica Casucci, Biagio De Angelis, Emmanuel Donnadieu, David Espie, Beatrice Greco, Richard Groen, Johannes B Huppa, Chahrazade Kantari-Mimoun, Bruno Laugel, Mary Mantock, Janet L Markman, Emma Morris, Concetta Quintarelli, Michael Rade, Kristin Reiche, Alba Rodriguez-Garcia, Juan Roberto Rodriguez-Madoz, Eliana Ruggiero, Maria Themeli, Michael Hudecek, Ibtissam Marchiq
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, 2022, 10 (5), pp.e003487. ⟨10.1136/jitc-2021-003487⟩
Guedan, S, Luu, M, Ammar, D, Barbao, P, Bonini, C, Bousso, P, Buchholz, C J, Casucci, M, De Angelis, B, Donnadieu, E, Espie, D, Greco, B, Groen, R, Huppa, J B, Kantari-Mimoun, C, Laugel, B, Mantock, M, Markman, J L, Morris, E, Quintarelli, C, Rade, M, Reiche, K, Rodriguez-Garcia, A, Rodriguez-Madoz, J R, Ruggiero, E, Themeli, M, Hudecek, M & Marchiq, I 2022, ' Time 2EVOLVE : predicting efficacy of engineered T-cells-how far is the bench from the bedside? ', Journal for Immunotherapy of Cancer, vol. 10, no. 5 . https://doi.org/10.1136/jitc-2021-003487
Journal for Immunotherapy of Cancer, 2022, 10 (5), pp.e003487. ⟨10.1136/jitc-2021-003487⟩
Guedan, S, Luu, M, Ammar, D, Barbao, P, Bonini, C, Bousso, P, Buchholz, C J, Casucci, M, De Angelis, B, Donnadieu, E, Espie, D, Greco, B, Groen, R, Huppa, J B, Kantari-Mimoun, C, Laugel, B, Mantock, M, Markman, J L, Morris, E, Quintarelli, C, Rade, M, Reiche, K, Rodriguez-Garcia, A, Rodriguez-Madoz, J R, Ruggiero, E, Themeli, M, Hudecek, M & Marchiq, I 2022, ' Time 2EVOLVE : predicting efficacy of engineered T-cells-how far is the bench from the bedside? ', Journal for Immunotherapy of Cancer, vol. 10, no. 5 . https://doi.org/10.1136/jitc-2021-003487
International audience; Immunotherapy with gene engineered CAR and TCR transgenic T-cells is a transformative treatment in cancer medicine. There is a rich pipeline with target antigens and sophisticated technologies that will enable establishing thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68b756f652c2c9fc9422e4028da4fca1
https://doi.org/10.1136/jitc-2021-003487
https://doi.org/10.1136/jitc-2021-003487
Publikováno v:
Bulletin du Cancer
Bulletin du Cancer, 2022, 109 (11), pp.11S11-11S20. ⟨10.1016/S0007-4551(22)00464-7⟩
Bulletin du Cancer, 2022, 109 (11), pp.11S11-11S20. ⟨10.1016/S0007-4551(22)00464-7⟩
International audience; Contribution of immunotherapy in the treatment of advanced biliary tract cancer Biliary tract cancers (BTC) are rare tumors with a poor prognosis. Their treatment, at an advanced stage, relies on combinations of chemotherapies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81c351932a9a910575a9be4e9bea484e
https://univ-rennes.hal.science/hal-03930644
https://univ-rennes.hal.science/hal-03930644
Autor:
Bijal D. Shah, Armin Ghobadi, Olalekan O. Oluwole, Aaron C. Logan, Nicolas Boissel, Ryan D. Cassaday, Thibaut Leguay, Michael R. Bishop, Max S. Topp, Dimitrios Tzachanis, Kristen M. O’Dwyer, Martha L. Arellano, Yi Lin, Maria R. Baer, Gary J. Schiller, Jae H. Park, Marion Subklewe, Mehrdad Abedi, Monique C. Minnema, William G. Wierda, Daniel J. DeAngelo, Patrick Stiff, Deepa Jeyakumar, Jinghui Dong, Sabina Adhikary, Lang Zhou, Petra C. Schuberth, Imi Faghmous, Behzad Kharabi Masouleh, Roch Houot
Publikováno v:
Journal of hematology & oncology, vol 15, iss 1
Journal of Hematology and Oncology
Journal of Hematology and Oncology, 2022, 15 (1), pp.170. ⟨10.1186/s13045-022-01379-0⟩
Journal of Hematology and Oncology
Journal of Hematology and Oncology, 2022, 15 (1), pp.170. ⟨10.1186/s13045-022-01379-0⟩
Background Brexucabtagene autoleucel (KTE-X19) is an autologous anti-CD19 CAR T-cell therapy approved in the USA to treat adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (R/R B-ALL) based on ZUMA-3 study results. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5e535f707491b52d5e9e38e372d3320
https://pubmed.ncbi.nlm.nih.gov/36494725
https://pubmed.ncbi.nlm.nih.gov/36494725
Autor:
Marie Véron, Sylvie Chevret, Jean-Jacques Grob, Marie Beylot-Barry, Philippe Saiag, Aude Fléchon, Benoit You, Eve Maubec, Thomas Jouary, Elise Toulemonde, Philippe Jamme, Laëtitia Gambotti, Assia Lamrani-Ghaouti, Alain Dupuy, Céleste Lebbe, Nicole Basset Seguin, Nadine Houede, Marie-Thérèse Leccia, Fanny Le Du, Michel de Pontville, Caroline Gaudy-Marquestre, Bernard Guillot, Clotilde Simon, Aurélien Marabelle, Laurent Mortier
Publikováno v:
European Journal of Cancer
European Journal of Cancer, 2022, 177, pp.103-111. ⟨10.1016/j.ejca.2022.09.013⟩
European Journal of Cancer, 2022, 177, pp.103-111. ⟨10.1016/j.ejca.2022.09.013⟩
International audience; Basal cell carcinoma (BCC) is the most common human malignancy. In most cases, BCC has slow progression and can be definitively cured by surgery or radiotherapy. However, in rare cases, it can become locally advanced or, even
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25e3fce35e724bd71f86e03f3346c539
https://pubmed.ncbi.nlm.nih.gov/36335780
https://pubmed.ncbi.nlm.nih.gov/36335780
Autor:
Coënon, Loïs, Villalba, Martin
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Frontiers, 2022, 13, pp.913215. ⟨10.3389/fimmu.2022.913215⟩
Frontiers in Immunology, Frontiers, 2022, 13, pp.913215. ⟨10.3389/fimmu.2022.913215⟩
International audience; Antibody-dependent cell-mediated cytotoxicity (ADCC) is a potent cytotoxic mechanism that is mainly mediated in humans by natural killer (NK) cells. ADCC mediates the clinical benefit of several widely used cytolytic monoclona
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c3b85a834634f937684ad7eebcdc0a5
https://doi.org/10.3389/fimmu.2022.913215
https://doi.org/10.3389/fimmu.2022.913215
Autor:
Marie-Therese Rubio, Roberta Di Blasi, Gilles Salles, Miguel A Perales, Kada Klouche, Muriel Picard, Pierre Sesques, Eric Mariotte, Michael Darmon, Boris Böll, Philippe R. Bauer, Sanjay Chawla, Kevin Rakszawski, Nahema Issa, Anne Huynh, Guillaume Cartron, Florence Rabian, Peter Borchmann, Michael Joannidis, Sabine Furst, Sophie de Guibert, Lara Zafrani, Patrice Ceballos, Nicolas Boissel, David Beauvais, Catherine Thieblemont, François-Xavier Gros, Alberto Mussetti, Gabriel Moreno-González, Adel Maamar, Florent Wallet, Faezeh Legrand, Julien Leroy, Quentin Quelven, Djamel Mokart, Valentin Ortiz, Christian Recher, Jakob Rudzki, Laura Platon, Pleun Hemelaar, Benoit Tessoulin, Reuben Benjamin, Sandrine Valade, Pedro Castro, Gennadii Galstian, Amélie Seguin, Peter Schellongowski, Anna Sureda, Alice Gallo De Moraes, Philipp Wohlfarth, Bruno Levy, Andry Van de Louw, Jorge Garcia Borrega, Julio Delgado, Ibrahim Yakoub-Agha, Nathalie Fégueux, Laveena Munshi, Yi Lin, Emmanuel Bachy, Stéphanie Harel, Sara Fernández, Bertrand Arnulf, Thomas Gastinne, Elie Azoulay, Didier Blaise, Amandine Le Bourgeois, Louis Voigt, Cécile Borel, Anne-Sophie Moreau, Christian Chabannon, Ulrich Jäger, Virginie Lemiale, Olga Gavrilina, Victoria Metaxa, Thomas Staudingert, Edouard Forcade
Publikováno v:
The Lancet Haematology
The Lancet Haematology, 2021, 8 (5), pp.e355-e364. ⟨10.1016/S2352-3026(21)00060-0⟩
The Lancet Haematology, Elsevier, 2021, 8 (5), pp.e355-e364. ⟨10.1016/S2352-3026(21)00060-0⟩
Lancet Haematology, 8, E355-E364
Dipòsit Digital de la UB
Universidad de Barcelona
Lancet Haematology, 8, 5, pp. E355-E364
The Lancet Haematology, 2021, 8 (5), pp.e355-e364. ⟨10.1016/S2352-3026(21)00060-0⟩
The Lancet Haematology, Elsevier, 2021, 8 (5), pp.e355-e364. ⟨10.1016/S2352-3026(21)00060-0⟩
Lancet Haematology, 8, E355-E364
Dipòsit Digital de la UB
Universidad de Barcelona
Lancet Haematology, 8, 5, pp. E355-E364
Summary Background Chimeric antigen receptor (CAR) T-cell therapy can induce side-effects such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS), which often require intensive care unit admission. The aim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10e0221bac10970ab09383fbb48e5504
https://hdl.handle.net/2066/241124
https://hdl.handle.net/2066/241124
Autor:
M.J. Reike, M.A. Ingersoll, D.C. Müller, T.C.M. Zuiverloon, T. Strandgaard, A.M. Kamat, S.B. Williams, R. Seiler, T. Todenhöfer, L. Dyrskjøt, R. Nawroth, P. Goebell, B. Schmitz-Dräger, J.P. Sfakianos, J. Meeks, A. Horowitz, P.C. Black
Publikováno v:
Urologic Oncology: Seminars and Original Investigations
Urologic Oncology: Seminars and Original Investigations, 2023, 41 (5), pp.211-218. ⟨10.1016/j.urolonc.2022.09.012⟩
Urologic Oncology: Seminars and Original Investigations, 2023, 41 (5), pp.211-218. ⟨10.1016/j.urolonc.2022.09.012⟩
International audience; Bacillus Calmette-Guerin (BCG) remains the only FDA-approved first-line therapy in patients with high-risk non-muscle invasive bladder cancer. Recurrences, even after adequate BCG therapy, are common and the efficacy of second
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d9a3de23738f1fdb748fd71fea881c2
https://pubmed.ncbi.nlm.nih.gov/36266219
https://pubmed.ncbi.nlm.nih.gov/36266219
Autor:
Michael Wang, Javier Munoz, Andre Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie José Kersten, Krimo Bouabdallah, Rashmi Khanal, Max S. Topp, Roch Houot, Amer Beitinjaneh, Weimin Peng, Xiang Fang, Rhine R. Shen, Rubina Siddiqi, Ioana Kloos, Patrick M. Reagan
Publikováno v:
Journal of Clinical Oncology, 94:02370. American Society of Clinical Oncology
Journal of clinical oncology, 94:02370. American Society of Clinical Oncology
Journal of Clinical Oncology
Journal of Clinical Oncology, 2023, 41 (3), pp.555-567. ⟨10.1200/JCO.21.02370⟩
Wang, M, Munoz, J, Goy, A, Locke, F L, Jacobson, C A, Hill, B T, Timmerman, J M, Holmes, H, Jaglowski, S, Flinn, I W, Mcsweeney, P A, Miklos, D B, Pagel, J M, Kersten, M J, Bouabdallah, K, Khanal, R, Topp, M S, Houot, R, Beitinjaneh, A, Peng, W, Fang, X, Shen, R R, Siddiqi, R, Kloos, I & Reagan, P M 2022, ' Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study ', Journal of Clinical Oncology, vol. 94, 02370 . https://doi.org/10.1200/JCO.21.02370
Journal of clinical oncology, 94:02370. American Society of Clinical Oncology
Journal of Clinical Oncology
Journal of Clinical Oncology, 2023, 41 (3), pp.555-567. ⟨10.1200/JCO.21.02370⟩
Wang, M, Munoz, J, Goy, A, Locke, F L, Jacobson, C A, Hill, B T, Timmerman, J M, Holmes, H, Jaglowski, S, Flinn, I W, Mcsweeney, P A, Miklos, D B, Pagel, J M, Kersten, M J, Bouabdallah, K, Khanal, R, Topp, M S, Houot, R, Beitinjaneh, A, Peng, W, Fang, X, Shen, R R, Siddiqi, R, Kloos, I & Reagan, P M 2022, ' Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study ', Journal of Clinical Oncology, vol. 94, 02370 . https://doi.org/10.1200/JCO.21.02370
PURPOSE Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL). Outcomes after a 3-year follow-up in the pivotal ZUMA-2 s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47eb8b07d9f89522a14b8f20081cb6f6
https://research.vumc.nl/en/publications/4b65d325-cfe4-4902-889d-10f9ca14f692
https://research.vumc.nl/en/publications/4b65d325-cfe4-4902-889d-10f9ca14f692
Publikováno v:
Revue des Maladies Respiratoires
Revue des Maladies Respiratoires, 2021, 38 (9), pp.865-872. ⟨10.1016/j.rmr.2021.06.005⟩
Revue Des Maladies Respiratoires
Revue des Maladies Respiratoires, 2021, 38 (9), pp.865-872. ⟨10.1016/j.rmr.2021.06.005⟩
Revue Des Maladies Respiratoires
Introduction La première vague de COVID-19 a nécessité des modifications des pratiques médicales selon les recommandations des sociétés savantes. En oncologie thoracique, le pembrolizumab a été doublé à 400 mg toutes les 6 semaines, le nivo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e56cff7e55ef6b2d9ab80f1a77b8a2c
https://hal.inria.fr/hal-03524426
https://hal.inria.fr/hal-03524426